# Apogee Therapeutics

Type: Company (APGE)

Source: GetYourBrief — https://getyourbrief.com/entity/apogee-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/apogee-therapeutics

## Recent coverage (4 stories, network-wide)

### How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print
2026-07-28 01:06:23 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Full story: https://getbiobrief.com/story/abbvie-q2-2026-rinvoq-skyrizi-growth

### Analyst Sentiment Shifts: Xponential Fitness Downgraded, Rocket Lab Initiated
2026-03-19 14:56:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Full story: https://getfinancebrief.com/story/analyst-sentiment-shifts-xponential-fitness-rocket-lab

### Analyst Sentiment Diverges for Biotech Leaders Apogee and Arcturus
2026-03-19 14:56:50 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Full story: https://getbiobrief.com/story/apogee-arcturus-analyst-ratings-divergence

### Mixed Analyst Sentiment Hits Biotech: Apogee and Arcturus Under Scrutiny
2026-03-19 14:56:16 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.
Full story: https://gethealthbrief.com/story/biotech-analyst-activity-apogee-arcturus

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.